Working… Menu
Trial record 20 of 468 for:    ESCITALOPRAM AND Cholinergic

Escitalopram for Agitation in Alzheimer's Disease (S-CitAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03108846
Recruitment Status : Recruiting
First Posted : April 11, 2017
Last Update Posted : January 17, 2019
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Dave Shade, JHSPH Center for Clinical Trials

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.

Condition or disease Intervention/treatment Phase
Dementia Drug: Escitalopram Drug: Placebo Phase 3

Detailed Description:
This study is designed to examine the efficacy and safety of escitalopram as treatment for agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant agitation, and their caregiver(s), will receive a structured psychosocial intervention. Participants not showing a response three weeks later will be randomized 1:1 to escitalopram (up to 15 mg/day) or a matching placebo. Participants will receive study drug for 12 weeks, with in-person visits at weeks 3, 6, 9, and 12, and with telephone contacts between in-person visits. Following the 12-week study treatment period, participants will be followed for another 12 weeks without receiving study drug. Participants who do show a response to the psychosocial intervention will not be randomized to study drug but will be followed for the 24-week follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 392 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Over-encapsulation
Primary Purpose: Treatment
Official Title: Escitalopram for Agitation in Alzheimer's Disease
Actual Study Start Date : January 3, 2018
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : August 2022

Arm Intervention/treatment
Experimental: Escitalopram
Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
Drug: Escitalopram
5-15 mg/day (target: 15mg/day if tolerated)
Other Name: Lexapro

Placebo Comparator: Placebo
1-3 capsules each containing placebo only once per day in the morning
Drug: Placebo
Masked placebo
Other Name: non-applicable

Primary Outcome Measures :
  1. modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC) [ Time Frame: after 12 weeks ]
    Clinical Global Impression of Change

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 109 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Alzheimer's dementia diagnosed clinically by the National Institute on Aging (NIA) and the Alzheimer's Association (AA) (2011 NIA/AA criteria)
  2. Mini-Mental State Examination (MMSE) score of 5-28 inclusive
  3. Meets the International Psychogeriatric Association (IPA) provisional criteria for agitation in cognitive disorders
  4. Clinically significant agitation/aggression as assessed by the Neuropsychiatric Inventory (NPI) for which either:

    • The frequency is 'Very frequently,' or
    • The frequency is 'Frequently' AND the severity is 'Moderate' or 'Marked'
  5. Provision of informed consent for participation in the study by both caregiver and participant (or, if participant is unable to provide informed consent, with surrogate consent and participant assent)
  6. Availability of a caregiver who spends at least several hours per week with the participant, supervises his/her care, is willing to accompany the participant to study visits, and is willing to participate in the study
  7. Stable (for ≥ 7 days) dosing of antipsychotics for agitation or psychosis, if being used at all
  8. A medication for agitation is appropriate, in the opinion of the study physician

Exclusion criteria

  1. Has major depression, as indicated by major depressive episode (MDE) in the past 90 days (meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria)
  2. Presence of another brain disease that fully explains the dementia, (e.g., extensive brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain injury, or multiple sclerosis)
  3. Residence in a skilled nursing or Long-Term Acute Care (LTAC) facility
  4. Contraindication to treatment with escitalopram as determined by a study physician, such as recent (30 days) use of monoamine oxidase inhibitors (MAOIs) or potential participant is hypersensitive to escitalopram or citalopram or any inactive ingredients
  5. Prior failed treatment attempt with citalopram or escitalopram for agitation after adequate trial, at minimally accepted dose
  6. Indication for psychiatric hospitalization or acute suicidality, in the opinion of the study physician
  7. Recent (< 7 days) changes in antipsychotics (including brexpiprazole), or psychosis (delusions or hallucinations) requiring a new or change in antipsychotic treatment (in the opinion of the study physician)
  8. Abnormal corrected QT interval using Bazett's formula (QTcB) as determined on enrollment ECG (defined as > 450 ms for men and > 470 ms for women)
  9. Recent (30 days) presence of severely reduced renal function (as identified by a Glomerular filtration rate (GFR) clearance < 30 mL/min) or reduced hepatic function
  10. Current treatment (within 7 days) with any of the following:

    • anticonvulsants (other than Dilantin for seizures)
    • antidepressants (other than trazodone, ≤ 50 mg per day at bedtime)
    • benzodiazepines (other than lorazepam), or
    • psychostimulants
  11. Recent (< 14 days) changes in Dextromethorphan/quinidine, prazosin, and pimavanserin
  12. Recent (< 14 days) use of medical marijuana
  13. Current participation in a clinical trial or in any study that may add a significant burden or affect neuropsychological or other study outcomes
  14. Significant communicative impairments that would affect participation in a clinical trial
  15. Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the potential participant to enroll in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03108846

Layout table for location contacts
Contact: Dave Shade, JD 4109558175
Contact: Stephan Ehrhardt, MD 4109558175

  Hide Study Locations
Layout table for location information
United States, Arkansas
Biomedical Research Foundation Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Prasad Padala    501-257-2537   
Contact: Chris Parkes    (501) 257-2504   
Principal Investigator: Prasad Padala, MD         
United States, California
Irvine Clinical Research Not yet recruiting
Irvine, California, United States, 92614
Contact: Tara Parnitvithikul    949-753-1663   
Principal Investigator: Elly Lee, MD         
University of California Los Angeles/VA Greater Los Angeles Healthcare System Recruiting
Los Angeles, California, United States, 90073
Contact: Katie Bayard    310-478-3711 ext 44572   
Contact: Alex Alas    (310)-478-3711   
Principal Investigator: David Sultzer, MD         
University of Southern California Keck School of Medicine Memory and Aging Center Recruiting
Los Angeles, California, United States, 90089
Contact: Mauricio Becerra, MD    323-442-7594   
Principal Investigator: Lon S. Schneider, MD         
Sub-Investigator: Sonia Pawluczy, MD         
United States, Florida
Miami Jewish Health Systems Recruiting
Miami, Florida, United States, 33137
Contact: Alexander Gomez    305-751-8626 ext 64101   
Principal Investigator: Marc Agronin, MD         
United States, Illinois
Northwestern University Feinberg School of Medicine Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Melody Fairchild    312-503-7071   
Contact: Marko Mihailovic    (312) 503-9096   
Principal Investigator: Michael Schrift, MD         
United States, Maryland
Maryland VA Health Care System Not yet recruiting
Baltimore, Maryland, United States, 21202
Contact: Joseph Schwartz    410-605-7358   
Principal Investigator: John Kasckow, MD         
Sheppard Pratt Health System Not yet recruiting
Baltimore, Maryland, United States, 21204
Contact: Marylu Ortiz    410-938-3135   
Principal Investigator: Scott Tyler Aaronson, MD         
Johns Hopkins University School of Medicine, Bayview Medical Center Recruiting
Baltimore, Maryland, United States, 21224
Contact: Nimra Jamil    410-550-9022   
Principal Investigator: Paul Rosenberg, MD         
Clinical Insights Recruiting
Glen Burnie, Maryland, United States, 20161
Contact: Norhan Ibrahim    410-768-2629   
Contact: Lawrence Adler   
Principal Investigator: Lawrence Adler, MD         
United States, Massachusetts
Alzheimer Disease Center Recruiting
Quincy, Massachusetts, United States, 02169
Contact: Jayaprabha Mane    617-302-6388   
Principal Investigator: Anil Nair, MD         
United States, Michigan
University of Michigan Program for Positive Aging Not yet recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Molly Turnwald    734-232-0393   
Principal Investigator: Helen Kales, MD         
United States, Nevada
Cleveland Clinic Lou Ruvo Center for Brain Health Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Monica Guerra    702-701-7893   
Principal Investigator: Alan Ritter, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Laura Simon-Pearson    646-774-8671   
Principal Investigator: Davangere P. Devanand, MD         
University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14620
Contact: Susan Salem-Spencer, RN, MSN    585-760-6562   
Principal Investigator: Anton Porsteinsson, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43221
Contact: Brooke Eiginger    614-293-9023   
Principal Investigator: Douglas Scharre, MD         
United States, Pennsylvania
Alzheimer Disease Research Center; University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Patricia Henderson    412-692-2703   
Principal Investigator: Oscar Lopez, MD         
Abington Neurological Associates, Ltd Recruiting
Willow Grove, Pennsylvania, United States, 19090
Contact: Cheryl Pugh    215-957-9250   
Principal Investigator: David Weisman, MD         
United States, South Carolina
Roper St. Francis Healthcare Recruiting
Charleston, South Carolina, United States, 29401
Contact: Arthur Williams    843-724-2053   
Principal Investigator: Jacobo Mintzer, MD         
United States, Texas
Baylor AT&T Memory Center Recruiting
Dallas, Texas, United States, 75231
Contact: Sarah Burris    214-818-2736   
Principal Investigator: Cindy Marshall, MD         
United States, Washington
Northwest Clinical Research Center Recruiting
Bellevue, Washington, United States, 98007
Contact: Leslie Gills    425-453-0404   
Principal Investigator: Shirin Schilling, MD         
Canada, Alberta
University of Calgary and Foothills Medical Centre Recruiting
Calgary, Alberta, Canada
Contact: Ramnik Sekhon    (403) 210-7737   
Principal Investigator: Zahinoor Ismail, MD         
Canada, Ontario
Lawson Health Research Institute/Parkwood Institute Recruiting
London, Ontario, Canada, N6C 0A7
Contact: Betsy Schaefer    (519) 455-5110   
Principal Investigator: Amer Burhan, MD         
Neuropsychopharmacology Research Group, Sunnybrook Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Abby Li    (416) 480-6100 ext 3185   
Principal Investigator: Nathan Herrmann, MD         
Centre for Addiction and Mental Health Recruiting
Toronto, Ontario, Canada, M6J1H4
Contact: Kyle Lago, MD    416-535-8501 ext 32911   
Principal Investigator: Bruce Pollock, MD         
Centre for Memory and Aging Recruiting
Toronto, Ontario, Canada
Contact: Mayrose Cornejo   
Principal Investigator: Giovanni Marotta, MD         
Sponsors and Collaborators
JHSPH Center for Clinical Trials
National Institute on Aging (NIA)
Layout table for investigator information
Study Chair: Constantine Lyketsos, MD, MHS Johns Hopkins University

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dave Shade, Director, S-CitAD Coordinating Center, JHSPH Center for Clinical Trials Identifier: NCT03108846     History of Changes
Other Study ID Numbers: S-CitAD
R01AG052510 ( U.S. NIH Grant/Contract )
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: January 17, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Dave Shade, JHSPH Center for Clinical Trials:
Alzheimer's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholinergic Antagonists
Cholinergic Agents
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents